NeuroMetrix, Inc. (NURO)
| Previous close | 3.5600 |
| Open | 3.7000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.5500 - 3.8050 |
| 52-week range | 2.7000 - 11.8400 |
| Volume | |
| Avg. volume | 45,082 |
| Market cap | 7.251M |
| Beta (5Y monthly) | 2.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.2700 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Mar 2007 |
| 1y target est | N/A |
GlobeNewswireNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age
- GlobeNewswire
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “This early adoption affirms the
Simply Wall St.NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)
NeuroMetrix ( NASDAQ:NURO ) Full Year 2023 Results Key Financial Results Revenue: US$5.90m (down 28% from FY 2022). Net...
